Edition:
India

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

4.78HKD
11 Aug 2020
Change (% chg)

HK$-0.09 (-1.85%)
Prev Close
HK$4.87
Open
HK$4.90
Day's High
HK$4.92
Day's Low
HK$4.76
Volume
9,210,905
Avg. Vol
22,270,447
52-wk High
HK$6.88
52-wk Low
HK$3.50

Select another date:

Mon, Jun 29 2020

BRIEF-Luye Pharma Group Says Clinical Trial Application Of Lurbinected Accepted By CDE Of PRC

* CLINICAL TRIAL APPLICATION OF LURBINECTEDIN FOR INJECTION (LY01017) ACCEPTED BY CENTRE FOR DRUG EVALUATION OF PRC Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Gets Acceptance For Clinical Trial Application Of LPM4870108 Tablets

* CLINICAL TRIAL APPLICATION OF LPM4870108 TABLETS ACCEPTED BY CENTRE FOR DRUG EVALUATION OF PRC Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Says IND Application Of LY03013 Accepted By CDE In China

* IND APPLICATION OF RIVASTIGMINE MULTI-DAY TRANSDERMAL PATCH (LY03013) ACCEPTED BY CDE IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Says Clinical Trial Application Of Injection Accepted

* CLINICAL TRIAL APPLICATION OF HYDROCHLORIDE IRINOTECAN FLOXURUDINELIPOSOME INJECTION ACCEPTED BY CENTRE FOR DRUG EVALUATION Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Gets Approval For Initiating Clinical Trial For Denosumab Injection In U.S.

* RECOMBINANT ANTI-RANKL FULLY HUMAN MONOCLONAL ANTIBODY INJECTION GOT APPROVAL FROM U.S. FDA TO INITIATE CLINICAL TRIALS Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Says Its Drug Rivastigmine Transdermal Patch Approved By Nmpa For Marketing

* LUYE PHARMA GROUP SAYS ITS DRUG RIVASTIGMINE TRANSDERMAL PATCH APPROVED BY NMPA FOR MARKETING Source text https://bit.ly/2Y8yGDK Further company coverage:

BRIEF-Luye Pharma Group Says Unit Signed An Exclusive Distribution And Marketing Agreement With Alvogen Korea

* UNIT SIGNED AN EXCLUSIVE DISTRIBUTION AND MARKETING AGREEMENT WITH ALVOGEN KOREA

BRIEF-Luye Pharma Says MAA For Rivastigmine MD Accepted For Review By EU Authorities

* MARKETING AUTHORIZATION APPLICATION FOR RIVASTIGMINE MD TO TREAT ALZHEIMER'S ACCEPTED FOR REVIEW BY EU COMPETENT AUTHORITIES Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Updates On Lipusu

* LIPUSU RECOMMENDED BY CSCO GUIDELINES ON DIAGNOSIS AND TREATMENT OF BREAST CANCER AS FIRST-LINE CHEMOTHERAPY Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Gets Approval For Clinical Trial For Ly03014 In China

* GROUP'S CLASS 1 NEW DRUG LPM3480392 INJECTION HAS OBTAINED APPROVAL FROM CENTRE FOR DRUG EVALUATION TO INITIATE CLINICAL TRIALS Source text for Eikon: Further company coverage:

Select another date: